Help stopping smoking. by unknown
-NVIRONFWS
Forum It's no longer just an annoyance.
Secondhand smoke exposes us to known carcinogens.
Tom Houston, American Medical Association
EnvironmentalHealth Perspectives, November 1996
Help Stopping Smoking
The American Heritage Dictionary ofthe
English Language defines "cigarette" as "a
small roll offinely cut tobacco for smoking,
usually enclosed in a wrapper of thin
paper." Cigarette companies are changing
this definition as they redesign the cigarette
to avoid the odor and pollution caused by
Help with the habit. A variety of new products ar
ensure fewer smokers and healthier air.
environmental tobacco smoke (ETS).
Meanwhile, they are also competing with
pharmaceutical companies for smokers as
these companies develop their own nicotine
delivery systems designed to help addicts
kick the habit.
For would-be quitters, nicotine delivery
systems including gum and the patch are
now joined by a nicotine inhaler, a nasal
spray, and two new low-smoke cigarettes.
These devices are equally effective, roughly
doubling the likelihood of success of quit-
ting to about 30%, says Dietrich
Hoffmann, associate director of the
American Health Foundation, a Valhalla,
New York-based research organization
devoted to the prevention of chronic and
environmentally induced disease. These
devices work by reducing withdrawal symp-
toms, which helps sustain smoking absti-
nence. They may also provide some of the
benefits that smokers obtain from cigarettes,
such as good mood and ability to pay atten-
tion, thereby reducing the smokers' depen-
dence on cigarettes.
None of these systems would be likely
to be addictive to current nonsmokers who
might try them, due to the low dose of
nicotine delivered. Some former smokers,
however, have been unable to shake their
dependence on smoking cessation devices
even after years of use. No matter, says
Michael Cummings, a senior research scien-
tist at the Roswell Park Cancer Institute in
Maryland. The dose of nicotine such
devices deliver is too small and delivery is far
too slow to contribute to heart disease as
cigarettes do. And nicotine is not consid-
ered carcinogenic. Even a
lollipop would be a
reasonable nicotine
delivery device,
says Cummings,
who advocates
"nicotine without
guilt."
In addition to
the nicotine deliv-
ery devices, one
antidepressant,
bupropion (market-
ed as Zyban), has
been approved by the
Food and Drug
Administration (FDA)
for smoking cessation.
In a large, double-blind,
e designed to placebo-controlled study published in the 23
October 1997 issue ofthe
New EnglandJournal ofMedicine, 300
mg/day ofbupropion raised the quit rate of
smokers to 23.10%, as compared to 12.4%
for the placebo group.
These new smoking cessation options
are important not only to smokers, but also
to the public health. From 1990 through
1994, an average of 181,000 smokers died
annually from cardiovascular disease attrib-
utable to their habit. Another 155,000 peo-
ple succumbed to cancers, and respiratory
diseases took yet another 91,000 lives,
according to the Centers for Disease
Control and Prevention (CDC). The CDC
estimates the death toll from lung cancer
due to ETS to be 3,000 annually. Other
sources put the number of all illnesses
caused by ETS at 50,000, says Gary A.
Giovino, chief of the epidemiology branch
ofthe CDC.
Low-smoke cigarettes greatly reduce
ETS, and one ofthem may mitigate smok-
ing-related adverse health effects. A smoker
seeking to quit can choose between two
low-smoke cigarettes currently on the mar-
ket-R. J. Reynolds's Eclipse and Philip
Morris's Accord. In the Eclipse, a carbon
tip heats a mixture oftobacco and glycerin,
instead of burning tobacco. Particles of
glycerin transport nicotine into the lungs.
The Accord is a smoking system that uses
Philip Morris's new electronic puff-activat-
ed lighter in combination with specially
manufactured cigarettes to burn the tobac-
co onlywhen the smoker inhales.
The levels of cigarette toxins in the
Eclipse are much lower than in convention-
al cigarettes, says R. J. Reynolds spokesman
Seth Moskowitz. In vitro tests including
genetic toxicity and cytotoxicity assays,
Ames tests, and sister chromatid exchange
were either negative or very marginally posi-
tive, says Moskowitz. Animal inhalation
studies and mouse skin-painting studies also
suggested that the Eclipse is comparatively
benign, he says.
This is not necessarily so, says John L.
Pauly, a cancer research scientist in the
department of immunology at the Roswell
Park Cancer Institute, who found that the
mouthpiece and a package of Eclipse ciga-
rettes were contaminated with fragments of
the glass fiber that is used to insulate the
lighter tip. Pauly's study, published in the
November 1998 issue of Cancer Epidemi-
ology, Biomarkers, and Prevention, found
95% of Eclipse filters to be contaminated
with 5-55 glass fibers. (In contrast, none of
the regular cigarettes used as controls were
contaminated with glass fibers.) Further-
more, experiments using smoking machines
demonstrated that the fibers would likely be
ingested or sucked into the lung.
Like asbestos, the glass fibers are proba-
bly physical carcinogens, says Pauly.
Macrophages, which would normally move
on after successfully eliminating foreign par-
ticles, persist in their attack on these inert
particles. This persistence damages the local
epithelium and probably eventually acti-
vates oncogenes and deactivates tumor sUp-
pressors. Asbestos causes malignant
mesothelioma, and the glass fibers probably
do likewise, says Pauly.
"The glass contamination problem is
serious enough that I would recommend
that [the Eclipse] be withdrawn immediate-
ly from the market," says Cummings.
"However, I believe that this is a correctable
problem, in which case an improved
Eclipse-like product might be worth pro-
moting as an alternative to smoking a con-
ventional cigarette."
Nicotine and carbon monoxide, the
major constituents of cigarette smoke
responsible for heart disease, are delivered to
the lung by the Eclipse in levels comparable
to those in conventional cigarettes, says Jack
E. Henningfield, vice president of research
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and health policy at Pinney Associates, a
consulting firm specializing in tobacco con-
trol and smoking cessation based in
Bethesda, Maryland. However, several other
compounds that contribute to heart disease,
including hydrogen cyanide, nitrogen
oxides, cadmium, and zinc, are absent from
the Eclipse.
Although the Eclipse does not eliminate
ETS, it reduces it by about 80%, according
to Moskowitz. Furthermore, he claims that
what smoke there is, is benign and dissipates
quickly compared to smoke from conven-
tional cigarettes.
The Philip Morris Accord is specially
manufactured for use in the puff-activated
lighter. Each puff activates one of the
lighter's eight sets of coils, in sequence,
singeing the cigarette's surface to generate
smoke. Between puffs, there is no combus-
tion, somewhat like turning the engine off
every time the car stops. The Accord's com-
bustion temperature-only 950°F, com-
pared to a conventional cigarette's
1,650°F-significantly reduces the amount
of chemical given off in two-thirds of the
species emitted, as compared to a conven-
tional cigarette, according to Mary
Carnovale, Philip Morris's manager of
media affairs. In particular, carbon monox-
ide is reduced by 94%, benzene by 98%,
benzo-a-pyrene by 98%, and tobacco-spe-
cific nitrosamines by 83%. The lower level
of carbon monoxide released from the
Accord would help to reduce the danger of
heart disease. Sidestream smoke, the smoke
that comes offthe tip ofa burning cigarette,
is virtually absent from the Eclipse, and
there is very little ETS.
Critics suspect that the Accord is less
toxic than the Eclipse, "but it's all specula-
tion," says Hoffman. He cautions that test-
ing of smoking cessation devices has been
done only by the manufacturers, without
input or oversight from the FDA.
The overall public health impact oflow-
smoke cigarettes depends on several unpre-
dictable factors: how many people will
switch from conventional cigarettes to low-
smokes, how many will switch who would
otherwise have quit, and whether low-
smoke cigarettes will attract new smokers
who otherwise would have refrained.
Cummings sees the low-smoke cigarettes as
a way for tobacco companies to encourage
smokers to keep puffing in the wake of
workplace bans. Such bans, he says, have
greatly encouraged quitting, because people
find they can live without cigarettes. Based
on the results of a study published in the
Summer 1997 issue of Tobacco Control, a
journal of the British Medical Association,
Cummings estimates that ifall work sites in
the United States were to ban smoking, an
additional 178,000 smokers would quit,
and those who continued to smoke would
consume 10 billion fewer cigarettes annual-
ly. "This led us to conclude that the tobacco
industry has a big financial stake in develop-
ing products that attempt to reduce ETS,
while at the same time keeping smokers
addicted to nicotine," he says.
Despite this conclusion, Cummings sees
the potential for banning conventional ciga-
rettes ifreplacements are available that satis-
fy addicts' cravings, and ifthe FDA can gain
regulatory control over tobacco products.
Cigarette companies are believed to be
developing other cigarette-like devices, and
Cummings foresees a plethora of new,
potentially safer products on the market in
the next decade.
Currently, the FDA is attempting to
gain jurisdiction over cigarettes and smoke-
less tobacco products, claiming that they are
nicotine delivery devices, and therefore fall
under its control. This claim is based on the
tobacco companies' manipulation of nico-
tine levels, says Scott Ballin, an independent
tobacco and health policy consultant. In
addition, internal memos from Philip
Morris state that the company is in direct
competition with pharmaceutical firms. But
cigar and pipe tobacco are exempt from this
claim because no evidence has surfaced that
companies have manipulated levels of nico-
tine in those products.
The FDA's effort to gain jurisdiction
has been challenged by tobacco companies
in a case that is expected to go the U.S.
Supreme Court in 1999. The FDA's acting
commissioner, Mitch Zeller, refused to
comment on these matters.
Greenhouse gases act as a blanket surround-
ing the earth-a blanket that grows thicker
and warmer with continued emissions.
The United States currently produces
about one-quarter of annual global green-
house gas emissions; an early action pro-
gram could augment current U.S. efforts to
reduce them. In a letter to President
Clinton, the task force wrote that an early
action program would also improve eco-
nomic performance and reduce local envi-
ronmental pollution.
The task force is made up of a diverse
group of representatives from government,
industry, and environmental groups.
Martin A. Spitzer, PCSD executive direc-
tor, says, "The important thing about these
principles is that the public thinks that no
one agrees on anything [regarding the
environment], but this diverse group actu-
ally agrees-the middle ground is one
where we are prudent and take steps with
everyone's participation."
The seven principles for early action
were devised as a means to guide the White
House and commercial enterprises in devel-
oping policies regarding early action, and
were designed to allow for the possibility
that the United States could agree to limit its
greenhouse gas emissions in the future. The
principles call for appropriate incentives to
spur earlyaction; broadly based participation
by government, industry, academia, non-
governmental organizations, communities,
and individuals; learning, innovation, flexi-
bility, and experimentation in creating new
ways to reduce emissions; formal credit for
greenhouse gas emissions reduction efforts;
accountability for producing emissions;
compatibility with other climate protection
strategies; and government leadership.
Early Action on
Climate Change
With average global tem-
peratures predicted to
rise by as much as 6.5°F
by the year 2100 under
current patterns of ener-
gy consumption, is it
really too soon to consid-
er new ways to do busi-
ness? Not according to
the Climate Change
Task Force of the
President's Council on
Sustainable Develop-
ment (PCSD). On 27
October 1998, the task
force submitted to
President Clinton seven
principles for the design
of an early action pro-
gram to reduce green-
house gas emissions.
SevenPrinciples for
ntabili for
mpatibility with othetr
ate protection s
nmient leadersi
Efforts to catalyze
voluntary early action
come at a time when
progress is slowly being
made in fleshing out the
details ofan internation-
al agreement to limit
greenhouse gas emis-
sions. At the fourth
Conference of the
Parties to the United
Nations Framework
Convention on Climate
Change, held in late
November 1998 in
Buenos Aires, Argentina,
the United States
became the sixtieth
nation to sign the Kyoto
Protocol. This treaty,
which has not been rati-
fied by the U.S. Senate,
calls for industrialized
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